This is true. In the biotech space the success of one company helps all other companies in the sector. Unfortunately, the reverse is also true.
I should mention that FTO is important in GBM. I would expect that there is a reasonable possibility that it would be synergistic with CAR-T treatments for this cancer type. Of course the only way to find out is run trials, but we already know that bisantrene is effective against GBM in vitro as a low dose FTO targeted agent.
Ann: Appendix 3Y - Dr Daniel Tillett, page-44
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.050(3.17%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.59 | $1.51 | $174.6K | 113.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2372 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 141 | 1 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |